Introduction Liaoning Weibang Biological Pharmaceutical Co., Ltd., founded in 1998, is located in Anshan City, Liaoning Province, China. In September 2020, it was acquired by Grand Pharmaceutical Group Limited, which is a member subsidiary of the Life Sciences Group in the pharmaceutical sector of the group. Relying on the group's strategic development plan, Liaoning Weibang is committed to improving the market share of the existing collagenase series and increasing the product indications, on the one hand, and on the other hand, it is committed to the investment in the construction of the project of "construction of API pilot test and industrialization base.
The company has two core products: Collagenase for injection and collagenase ointment. Collagenase for injection is a national class I new drug, which is clinically used for lumbar disc herniation that is ineffective after conservative treatment. Collagenase ointment belongs to class 3 chemical new drugs, which is clinically used for burn enzymatic debridement and promoting wound healing. |